This is a double-blind randomized controlled study. The study will last up to 16 weeks from the initial phone screen (it could take up to eight weeks to schedule and complete the initial screening process and schedule the 2 MRI visits). Once subjects have completed the screening process, they will begin the 8-week trial phase. Subjects will be assessed weekly throughout the study for efficacy and tolerability.
The investigators plan to recruit 80 participants with emotional dysregulation (ED) in the treatment arm. In addition, the investigators will aim to recruit 40age-, sex-, and parental-education matched participants without emotional dysregulation, and major psychopathology as Typically Developing (TD) control participants in the control arm.
Upon scheduling the baseline visit, only the emotional dysregulation (ED) participants will be randomized 1:1 to be exposed to NAC or placebo treatment for 8 weeks. Participants will complete baseline and post-treatment (endpoint) brain MRI acquisition. TD participants will complete the same screening and characterization process as the ED group and then will be invited to complete MRI eligibility screening and to be scanned twice, separated by an eight-week interval, but the TD will not complete the NAC treatment or receive a placebo. See Table 1 (Study Schema) for a complete list of characterization measures to be completed by each group.

Start Date01 Jan 2027

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT04381897

/ Not yet recruitingPhase 2IIT

Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study

This research project is a randomized cross-over pilot trial which aims to test the efficacy of N-acetylcysteine (NAC) for the treatment of Repetitive Behaviors (RB) and self-injurious behavior (SIB) in patients with Cornelia de Lange Syndrome (CdLs).
NAC is a known anti-oxidative stress and neuroprotective agent, which has been shown to decrease the occurrence of SIB such as skin picking. NAC has also shown partial response in trials for compulsive behaviors in Obsessive Compulsive Disorder (OCD) and related disorders in autism.
Cornelia de Lange syndrome (CdLS) is a genetic disorder with autistic features, including RBs and SIB. In this randomized clinical trial, participants with CdLS will be blindly assigned one of two possible treatment arms: 1) placebo (8 weeks) and NAC (8 weeks); or 2) NAC (8 weeks) and placebo (8 weeks), with an intermediate 2-week washout period.

Start Date01 Nov 2026

Sponsor / Collaborator

The Johns Hopkins University

NCT07227649

/ Not yet recruitingPhase 2IIT

NAC-REPAIR: N-Acetylcysteine-facilitated Redox-Immune Modulation for Post-surgical Analgesia and Injury Recovery

This pilot asks whether peri-operative N-acetylcysteine (NAC) improves recovery after common outpatient hand/foot-ankle surgery-specifically, does NAC reduce pain and opioid use and enhance function by modulating redox-inflammatory pathways? Primary objectives are to establish feasibility (accrual, adherence, follow-up), estimate NAC vs placebo effects on pain, function, and opioid consumption, and characterize inflammatory signatures that may predict response.
Methods: a single-site, double-blind, 1:1 randomized trial (N≈80) comparing NAC 1,200 mg twice daily for 14 days (starting pre-op) vs matching placebo; daily e-diaries for POD0-14; standardized outcomes (PROMIS Pain Interference; QuickDASH or FAAM; PGIC; opioid MME); and small blood draws pre-surgery and at two follow-up visits for cytokine profiling.

Start Date15 Oct 2026

Sponsor / Collaborator

University of Arizona

[+1]

100 Clinical Results associated with Acetylcysteine

100 Translational Medicine associated with Acetylcysteine

100 Patents (Medical) associated with Acetylcysteine

30,174

Literatures (Medical) associated with Acetylcysteine

31 Dec 2026·DRUG DELIVERY

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Review

Author: O'neill, Allison F ; Huitema, Alwin D R ; Bleyer, Archie ; Bouffet, Eric ; Streefkerk, Nienke ; Masroor, Amirhossein ; Sullivan, Michael ; Fresneau, Brice ; Maibach, Rudolf ; Van Grotel, Martine ; Hoetink, Alexander E ; Rajput, Kaukab M ; Papadakis, Vassilios ; Knight, Kristin ; Brock, Penelope R ; Geller, James I ; Kogner, Per ; Veal, Gareth J ; Ansari, Marc ; Van Den Heuvel-Eibrink, Marry M

Cisplatin-induced hearing loss (CIHL) in pediatric cancer patients is an irreversible and highly prevalent adverse effect with a devastating impact on quality of life. Sodium thiosulfate (STS) has recently been approved for systemic administration as an otoprotective agent in children. However, implementation of systemic STS has its challenges, and there is currently limited evidence to support local STS for children. This review investigates the potential value of locally administered otoprotective agents other than STS with a focus on future pediatric implementation. We conducted a systematic review on the efficacy and safety of locally applied non-STS otoprotective agents in in vivo settings. This included a summary of investigated drug delivery methods and administration routes. We identified 70 preclinical and eight clinical studies. Agents were categorized based on their biological mechanisms: anti-inflammatory, chemical deactivators, calcium blockers, biologicals, and miscellaneous mechanisms. Preclinical studies investigated 45 different agents. Dexamethasone and N-acetylcysteine were identified as efficacious agents recurrently and progressed to clinical trials. Dexamethasone was investigated in three randomized clinical trials (RCTs) and three non-randomized clinical studies and showed statistically significant but not clinically relevant benefit in two trials. N-acetylcysteine was investigated in two clinical trials and one RCT and was minimally effective in the RCT and in one clinical study. Our review did not identify available studies of local alternative otoprotective agents that could reliably replace systemic STS in terms of safety and efficacy for pediatric patients. Further research on the optimal dosage, delivery method, and timing of otoprotective agents is needed.

31 Dec 2026·CNS oncology

Arginine deprivation induces prolonged autophagy activation and ROS-dependent cell death in glioblastoma multiforme

Article

Author: El-Jawhari, Yasmin ; Saad, Rawan ; Sarieddine, Majd ; El-Husseini, Nour ; El-Sibai, Mirvat ; Abi-Habib, Ralph J. ; Shaheen, Maha ; Abdelkhalek, Maya

BACKGROUND:

Arginine deprivation was shown to be selectively cytotoxic to GBM cells with cell death being caspase-independent, non-apoptotic. In this study, we assess the impact of prolonged arginine deprivation on GBM cells, the potential activation of autophagy, the mechanism of its activation, and its impact on cell cytotoxicity.

METHODS:

GBM cell lines A172 and U251 were used in this study and arginine deprivation was induced by a cobalt-substituted, PEGylated human arginase I [HuArgI (Co)-PEG5000].

RESULTS:

Arginine deprivation induced prolonged cytotoxicity up to 120 hours post-treatment. Cytotoxicity persisted despite cells overexpressing ASS-1. Arginine deprivation also induced a marked and sustained activation of autophagy, starting at 24 hours and lasting up to 120 hours post-treatment. Autophagy was shown to induce cell death since its inhibition by chloroquine significantly decreased cytotoxicity, indicating that the extensive activation of autophagy is resulting in cell death of GBM cells. Moreover, ROS was shown to accumulate in treated cells and neutralizing ROS using NAC did not affect the autophagic response but led to a complete reversal of cytotoxicity, demonstrating that death by autophagy is dependent on ROS generation.

CONCLUSION:

Arginine deprivation leads to sustained activation of autophagy and subsequent ROS-dependent cell death in GBM cells.

31 Dec 2026·Adipocyte

Lack of receptor for advanced glycation end products attenuates obesity-induced adipose tissue senescence in mice

Article

Author: Chen, Ni ; Ma, Xiaoyu ; Xu, Jin ; Li, Ziyu ; Wu, Jianbo ; You, Jingcan ; Wu, Jiaqi ; Du, Zuoqin ; Zhang, Tao

The receptor for advanced glycation end products (RAGE) and its ligands are critical drivers of adipose tissue inflammation. While RAGE expression increases in ageing cells and pathological conditions, its specific role in high-fat diet (HFD)-induced adipose tissue senescence remains to be fully elucidated. In this study, we investigated the function of RAGE in the development of adipose tissue senescence associated with obesity. We observed that HFD-fed RAGE-deficient (RAGE^-/-) mice exhibited significantly reduced body weight and adipocyte hypertrophy compared to wild-type (WT) controls. At the molecular level, RAGE^-/- mice displayed lower mRNA expression of cell cycle regulators and markers of the senescence-associated secretory phenotype. This anti-senescent phenotype was accompanied by decreased reactive oxygen species (ROS) production and elevated expression of anti-oxidant genes. Mechanistically, the lack of RAGE resulted in the upregulation of silent information regulator type 1 (SIRT1) in adipose tissues. Notably, the inhibition of SIRT1 reversed these anti-senescent effects and attenuated anti-oxidant gene expression in RAGE-deficient mice. Furthermore, while antioxidant treatment with N-acetylcysteine (NAC) reduced p53 in WT mice, it failed to fully suppress p16 and p21, whereas NAC treatment in RAGE^-/- mice significantly downregulated all senescence markers, suggesting a synergistic protective effect. In conclusion, our results demonstrated that RAGE deficiency improved anti-oxidant properties and prevents adipocyte senescence via the SIRT1 signalling pathway, highlighting a potential therapeutic target for obesity-associated tissue dysfunction.

134

News (Medical) associated with Acetylcysteine

12 Aug 2026

·www.biospace.com

Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

TORONTO, ON / ACCESS Newswire / August 12, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced positive results from a research study conducted by Defence Research and Development Canada - Suffield Research Centre ("DRDC") evaluating bucillamine in an established animal model of nerve-agent exposure. The study compared bucillamine with N-acetylcysteine ("NAC"), an antioxidant previously evaluated in this research model. The objective was to examine clinical signs, seizure activity and the preservation of GABA receptor signaling in the brain following exposure. Animals pretreated with either bucillamine or NAC demonstrated preservation of hippocampal GABA receptor post-synaptic density compared with control animals. Bucillamine appeared comparable to NAC on this measured endpoint. All study groups displayed similar signs of seizure activity and other clinical effects associated with exposure. Importantly, no pulmonary hemorrhage was observed in the bucillamine-treated group, whereas it was observed in the NAC-treated group. No signs of cerebral hemorrhage were observed in either group. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); "The DRDC research study provides a scientific basis for continuing to evaluate bucillamine in combination with established treatments for nerve-agent exposure," said Michael Frank, Chief Executive Officer of Revive. "Bucillamine demonstrated preservation of the measured GABA receptor endpoint comparable to NAC, while pulmonary hemorrhage observed in the NAC-treated group was not observed in the bucillamine-treated group. These findings support our broader objective of evaluating bucillamine's potential role in biodefence and pandemic preparedness, and we intend to explore further related opportunities with government, defence, and other strategic organizations." DRDC will continue its research on bucillamine through additional confirmatory studies scheduled to begin in Q4-2026. Additional research will evaluate its potential effects on brain injury, oxidative stress, response to standard treatment and respiratory function. In addition, the current research findings and further research may help Revive evaluate potential development, funding, and collaboration opportunities with government, defence, and strategic organizations. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit . For more information, please contact: Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1-888-901-0036 Email: mfrank@revivethera.com Website: SOURCE: Revive Therapeutics Ltd. View the original press release on ACCESS Newswire

Clinical Result

01 Jul 2026

·www.apotex.com

Apotex completes previously announced strategic transaction with Cumberland Pharmaceuticals

TORONTO, July 1, 2026 /CNW/ – Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic transaction with Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. biopharmaceutical company, to integrate Cumberland's U.S. branded businesses into Apotex. With the completion of the strategic transaction, Apotex adds a portfolio of established branded medicines to its U.S. business, expanding its specialty and hospital-focused presence across key therapeutic areas including acute care, oncology, infectious disease, and gastroenterology. "This milestone strengthens our ability to support patients and healthcare providers across the United States," said Jeff Watson, President & CEO of Apotex. "We look forward to integrating these important medicines into our portfolio and expanding access to high-quality treatments." "We are pleased to have completed this strategic transaction with Apotex, which will create more critical mass to better support patient care," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. The portfolio includes well-established brands, including Kristalose®, Caldolor®, Sancuso®, Vibativ®, Acetadote®, Vaprisol®, and Talicia®, which are prescribed across hospitals, oncology, infectious disease, and gastroenterology settings. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more at www.apotex.com Forward-Looking Statements This press release may contain forward-looking information within the meaning of applicable securities laws, including statements about strengthening Apotex's ability to support patients and healthcare providers across the United States, Apotex integrating the acquired medicines into its portfolio and expanding access to high-quality treatments, and creating critical mass to better support patient care. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances. Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by Apotex to be appropriate and reasonable as of the date of this release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, factors discussed under “Risk Factors” in Apotex's public filings and include risks associated with Apotex being unable to support patients and healthcare providers across the United States, failure to integrate the acquired medicines in Apotex's portfolio, failure to expand access to high-quality treatments and failure to create critical mass to better support patient care. Apotex undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is a Nashville-based biopharmaceutical company focused on developing new therapies for rare diseases. The company is advancing a late-stage pipeline of product candidates through a series of late-stage clinical studies. The treatments are being developed across multiple therapeutic areas to address serious patient conditions that represent unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. For more information, please visit www.cumberlandpharma.com Media contact: media@apotex.com

Phase 2Acquisition

24 Jun 2026

·www.prnewswire.com

Roamin Cat Should Have Held the Onions

Frisky Feline Poisoned by Discarded Sliders MINNEAPOLIS, June 24, 2026 /PRNewswire/ -- Sometimes a pet is named for his appearance, such as Spot or Red. Others practically name themselves by their behavior. From the moment Michael Nihart saw his new cat investigating the entire house, it was pretty clear that Roamin had his name, and that he likes mischief. "He's like a dog in a cat's body," joked Lisa Nihart, Michael's mom. "He's always getting into trouble and trying to sneak outside." Continue Reading "Cats often have very high curiosity, which in this case could have actually killed him." Post this Roamin found out the hard way how dangerous ingesting onions are for cats. That curious nature, however, can get pets into trouble. "Cats often have very high curiosity, which in this case could have actually killed him," said Dr. Renee Schmid, a senior veterinary toxicologist and director of Veterinary Medicine at Pet Poison Helpline. "Roamin got into the trash and ingested two White Castle™ sliders with diced onion. Although the high fat and salt content can cause gastrointestinal upset, it was the onions that caused us the most concern." In honor of National Onion Day on June 27, the toxicology experts at Pet Poison Helpline want to warn pet lovers that toxic doses of onions by pets can result in oxidative damage to the red blood cells, making the cells more likely to rupture. It can also cause gastroenteritis, resulting in nausea, oral irritation, drooling, abdominal pain, vomiting and diarrhea. With onions, poisoning may have a delayed onset, and clinical signs may not be apparent for several days. Left untreated, it can result in death. "Not only do White Castle sliders have onions on them, but they also have onions in them," Lisa Nihart explained. "Being a veterinary technician, I knew onions were dangerous to cats, so I called Pet Poison Helpline. They recommended I take Roamin to the hospital." Roamin was taken to Wellhaven Pet Health Maple Grove for evaluation and treatment. "Nobody had any idea what to do," Lisa Nihart said. "It's a good thing we already had a case started with Pet Poison Helpline, because the hospital team was able to begin evaluating her immediately. Because I'm a tech, I thought I could monitor and treat him at home." Based on the timing of the ingestion, it was too late to induce vomiting or provide additional decontamination, so an anti-emetic was given, bloodwork was performed and subcutaneous fluids were administered. Nihart decided to take Roamin home and was given antioxidants to administer to help minimize red cell damage and advised to recheck bloodwork every two to three days to evaluate for anemia. Roamin would also need to return the veterinary hospital if he was lethargic, not eating, or had any other abnormal behavior. After several days, Michael noticed that Roamin was still not his normal rambunctious self and had pale coloring to his gums, which could indicate anemia. He insisted that something was wrong, and his mom took the cat back to the hospital for a recheck of his bloodwork and potentially additional treatment. By that time, Roamin's blood cells were showing signs of significant damage. Roamin's red blood cell count was dangerously low, and his bloodwork was consistent with red blood cell damage caused by the toxic components of onions. "We recommended a very aggressive treatment," Dr. Schmid said. "One of our veterinary toxicologists who managed Roamin's case advised to start intravenous fluids, an additional antioxidant and glutathione replacer called N-Acetylcysteine, as well as additional antioxidants. Fortunately for Roamin, he remained stable enough to not need a blood transfusion." Roamin remained in the hospital for several days and continued to have bloodwork monitoring for two weeks to ensure his red blood cells had returned to normal, healthy numbers. While Roamin's exposure had a happy ending, onion poisoning, and any Allium species in general, be challenging to relay the potential severity with pet owners. Many pet foods and products contain onion or garlic to enhance flavoring. When it comes to determining the toxicity of garlic and onions, the dose matters. The amounts added to pet products are well below a dose where poisoning could occur, but that doesn't mean those foods aren't toxic at larger doses. Also, because signs of poisoning often do not develop until several days to a week after the ingestion, many pet owners will assume their pet is out of the woods and may choose not to be more aggressive with their initial care. Unfortunately, this can result in fatal consequences. "I'm really glad Michael is so focused on Roamin," Lisa Nihart added. "He noticed the changes in his behavior and talked me into going back to the hospital. It probably saved Roamin's life." Pet Poison Helpline created Toxin Tails to educate the veterinary community and pet lovers on the many types of poisoning dangers facing pets, both in and out of the home. All the pets highlighted in Toxin Tails have been successfully treated for the poisoning and fully recovered. About Pet Poison Helpline Pet Poison Helpline®, your trusted source for toxicology and pet health advice in times of potential emergency, is available 24 hours, seven days a week for pet owners and veterinary professionals who require assistance treating a potentially poisoned pet. Per incident and subscription service options are available. We are an independent, nationally recognized animal poison control center triple licensed by the Boards of Veterinary Medicine, Medicine and Pharmacy providing unmatched professional leadership and expertise. Our veterinarians and board-certified toxicologists provide treatment advice for all species, including dogs, cats, birds, small mammals, large animals and exotic species. As the most cost-effective option for animal poison control care, Pet Poison Helpline's fee of $89 per incident includes follow-up consultations for the duration of the case. The company also offers pethelpline(SM) and pethelplinePRO(SM) subscription services directly to pet lovers. Based in Minneapolis, Pet Poison Helpline is available in North America by calling 800-213-6680. Additional information, including a chat feature for pet owners, can be found online at . Contact: Curtis Steinhoff Pet Poison Helpline® (602) 300-8466 [email protected] SOURCE Pet Poison Helpline 21% more press release views with Request a Demo

100 Deals associated with Acetylcysteine

External Link

KEGG	Wiki	ATC	Drug Bank
D00221	Acetylcysteine	V03AB23 S01XA08 R05CB01	DB06151

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchitis	China	Parexel China Co.,Ltd.	13 May 2025
Nails, Ingrown	Japan	Maruho Co., Ltd.	27 Mar 2023
Acetaminophen overdose	Australia	Pfizer Australia Pty Ltd.	17 Jul 2006
Pulmonary Disease, Chronic Obstructive	China	Jiangsu Jibeier Pharmaceutical Co. Ltd.	01 Jan 1985
Asthma	Japan	Sannova KK	05 Jan 1965
Bronchiectasis	Japan	Sannova KK	05 Jan 1965
Bronchitis, Chronic	Japan	Sannova KK	05 Jan 1965
Cystic Fibrosis	Japan	Sannova KK	05 Jan 1965
Laryngitis	Japan	Sannova KK	05 Jan 1965
Pharyngitis	Japan	Sannova KK	05 Jan 1965
Pneumonia	Japan	Sannova KK	05 Jan 1965
Pulmonary Emphysema	Japan	Sannova KK	05 Jan 1965
Pulmonary Tuberculosis	Japan	Sannova KK	05 Jan 1965
Chemical and Drug Induced Liver Injury	United States	Apothecon LLC	14 Sep 1963
Liver Injury	United States	Apothecon LLC	14 Sep 1963

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Bronchitis	Phase 3	China	Zambon SpA	21 Jun 2019
Acute Bronchitis	Phase 3	China	Zambon Switzerland Ltd.	21 Jun 2019
Idiopathic Pulmonary Fibrosis	Phase 3	Belgium	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	France	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Germany	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Italy	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Netherlands	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Spain	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	United Kingdom	Zambon SpA	01 Mar 2000
Common Cold	Phase 2	Canada	Novartis AG	01 Jan 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04627922 (NAC_CUD-TUD, CTgov)	Phase 4	Tobacco Use Disorder \| Marijuana Abuse \| Unspecified drug dependence	41	Cognitive behavioral therapy (CBT)+N-Acetyl cysteine (N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy)	owtofqgwcs(gjybyzboex) = sxzauydraf uhfwxuhnaq (fvhsmlipkj, 10.91) View more	-	11 Aug 2026
				Placebo comparator (Placebo Comparator: Placebo & Cognitive Behavioral Therapy)	owtofqgwcs(gjybyzboex) = myahjctmtp uhfwxuhnaq (fvhsmlipkj, 11.52) View more
NCT03822637 (ENACT, CTgov)	Phase 4	Asthma	4	N-Acetylcysteine (NAC) (20% N-Acetylcysteine (NAC))	ozncqhfgdo(fovycguzkt) = afmumlipqt hcecbztkqa (jsxfmaczco, 3.74) View more	-	11 Jun 2026
				Placebo+NAC+albuterol (Placebo)	ozncqhfgdo(fovycguzkt) = euqtxdygzi hcecbztkqa (jsxfmaczco, 6.49) View more
NCT04481048 (DoDNAC, CTgov)	Phase 2	Neurofibromatosis 1	25	N-Acetyl cysteine (N-Acetylcysteine (NAC))	igzujazupb(dirjvigvyi) = cvdycbjide mgqyhrjavn (okppjuxrrd, 9.3) View more	-	05 Jun 2026
				Placebo (Placebo)	igzujazupb(dirjvigvyi) = bmaeefcief mgqyhrjavn (okppjuxrrd, 12.7) View more
NCT03220776 (Pubmed \| Transl Psychiatry)	Phase 2	Alcohol Use Disorder	54	N-acetylcysteine (NAC)	bytcaodyso(gtowcgrigf) = xqjqstkryw gwyinfisnu (pfuqysypyr, 4.6) View more	Positive	03 Jun 2026
				Placebo	bytcaodyso(gtowcgrigf) = pcrlqacbns gwyinfisnu (pfuqysypyr, 4.55) View more
DDW2026	Not Applicable	Hepatitis, Alcoholic	10,248	NAC+steroid	livaiswkdc(ccedfiaxug) = the incidence of HRS/ARF and MALOs was comparable between groups at 1,3,6, and 12 months aszhcsywng (wxsjhkmyfa ) View more	Negative	02 May 2026
				steroid only
NCT06581783 (Pubmed \| J Gastroenterol Hepatol)	Not Applicable	-	1,200	Placebo	okdubuaajc(bdabpgafms) = blyjovzmtr uflglingpo (zacgezhfhl ) View more	Positive	10 Apr 2026
				Simethicone + NAC (premedication to endoscopy interval of 10-20 min)	okdubuaajc(bdabpgafms) = xocymeuprc uflglingpo (zacgezhfhl ) View more
NCT03911414 (CTgov)	Phase 4	Dietary Supplement \| Depressive Disorder \| Emotional lability ... View more	27	Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol)	seuqmaabcm(vyrfyrzele) = pkscfzxokh duqcmtwbzs (vifktohdrc, 5.5) View more	-	18 Mar 2026
				Open-label Treatment with N-acetylcysteine (N-acetylcysteine)	seuqmaabcm(vyrfyrzele) = nculucoggc duqcmtwbzs (vifktohdrc, 5.9) View more
NCT05944458 (Pubmed \| Environ Toxicol Pharmacol)	Phase 4	Thrombocytopenia	250	N-acetylcysteine (IV NAC) 600 mg	hqvdasckxn(jdvncqpmhy) = bfyuaaflwz vltmqbnqsg (zhtpxngtiu ) View more	Positive	01 Mar 2026
				Placebo	hqvdasckxn(jdvncqpmhy) = wjaflsznze vltmqbnqsg (zhtpxngtiu ) View more
NCT04013555 (TrypNAC-II, CTgov)	Phase 1/2	Schizoaffective disorder \| Schizophrenia	88	Tryptophan+N-acetylcysteine (NAC) (N-acetylcysteine & Tryptophan)	pmpxhionsg(lipwljgkqn) = hcvfcynhhw ftbceqoalh (usqavqiauy, 1.89) View more	-	11 Feb 2026
				Placebo+Tryptophan (Placebo & Tryptophan)	pmpxhionsg(lipwljgkqn) = uvcuciwvax ftbceqoalh (usqavqiauy, 1.22) View more
NCT04155632 (COCA, CTgov)	Phase 2	Cocaine-Related Disorders	32	cTBS (Active Theta Burst Stimulation)	nvtkchyihm(uzgqidbexr) = kuqnqgffaz etzjctyzzd (tbybndbgaj, 0.0080) View more	-	24 Sep 2025
				cTBS (Sham Theta Burst Stimulation)	nvtkchyihm(uzgqidbexr) = quhbcypkco etzjctyzzd (tbybndbgaj, 0.0105) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis